Consent given pursuant to Sections 14 and 14A for the importation and supply of the therapeutic goods specified by Pfizer Australia

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, aims to regulate the supply of therapeutic goods to ensure public health and safety. On 20 March 2015, the delegate of the Secretary of the Department of Health granted consent to Pfizer Australia Pty Ltd for the importation and supply of certain methotrexate and cabergoline products that did not conform to the child-resistant packaging requirements outlined in Therapeutic Goods Order No. 80. This consent was provided to address a temporary supply issue while ensuring the safety of these medications, which are critical for patient care, by imposing specific conditions, including the provision of child-resistant closures and detailed instructions to pharmacists to mitigate risks to children.

Scope and Application

The Therapeutic Goods Act 1989 applies to a wide range of therapeutic goods, including medicines, medical devices, and blood and blood components, and regulates their import, supply, and advertising. The Act applies to individuals, companies, and other entities that manufacture, supply, or import therapeutic goods within Australia. The legislation has a national reach, governing therapeutic goods across all states and territories of Australia. The Act includes provisions for exemptions, particularly for research purposes, clinical trials, and personal use imports. It also provides for exclusions such as food, cosmetics, and most devices that are not classified as therapeutic goods. The Act’s scope can be further defined or refined through subordinate instruments such as regulations and orders, which provide more specific guidelines and standards for particular classes of therapeutic goods. The Therapeutic Goods Act 1989 thus serves as a comprehensive regulatory framework that ensures the safety, quality, and efficacy of therapeutic goods available in Australia.

Key Provisions

The Therapeutic Goods Act 1989, as amended by the 2015 Gazette (sections 14 and 14A), includes specific provisions allowing for the importation and supply of certain therapeutic goods that do not fully comply with existing regulations. In this instance, the Act permitted the importation and supply of methotrexate and cabergoline products that did not conform with the child-resistant packaging requirements outlined in Therapeutic Goods Order No. 80. These products include methotrexate (METHOBLASTIN) 2.5 mg and 10 mg tablet bottles, and cabergoline (CABASER) 1 mg and 2 mg tablet bottles, as well as cabergoline (DOSTINEX) 0.5 mg tablet bottles. Under the authority of the Act, the delegate of the Secretary of the Department of Health granted consent for these products to be imported and supplied by Pfizer Australia Pty Ltd, but only for a limited period from 20 March 2015 until 30 September 2015. This consent was granted with specific conditions aimed at ensuring the safety of the products. Each unit of these products must be supplied with a companion child-resistant item and instructions on how to implement the corrective action. Additionally, "Dear Pharmacist" letters were distributed to dispensing pharmacists, advising them to take necessary steps to ensure the containers are child-resistant before dispensing the products to the public. The dispensing labels for the replacement bottles or closures for Cabaser and Dostinex tablets must include specific details as outlined in the conditions. The Therapeutic Goods Act 1989 imposes specific obligations on entities importing or supplying therapeutic goods that do not meet regulatory standards. In this case, Pfizer Australia Pty Ltd must ensure that each unit of the specified methotrexate and cabergoline products is accompanied by a child-resistant item and instructions for corrective action. Furthermore, the company must distribute the "Dear Pharmacist" letters to ensure that pharmacists are aware of the necessary steps to ensure child resistance before dispensing the products. Failure to comply with these obligations could result in significant legal and reputational consequences. Breach of the conditions attached to the consent may result in civil or criminal penalties under the Therapeutic Goods Act 1989. While the specific penalties are not detailed in the gazette, the Act provides for a range of enforcement actions that could be taken against non-compliant entities. These may include fines, product recalls, or more severe legal actions depending on the nature and extent of the breach. The consequences underscore the importance of adhering to the conditions and ensuring that all therapeutic goods supplied meet the required safety standards.